NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
0.6372
Dollar change
+0.0585
Percentage change
10.11
%
IndexRUT P/E- EPS (ttm)-0.60 Insider Own27.29% Shs Outstand129.54M Perf Week-11.86%
Market Cap186.50M Forward P/E- EPS next Y-0.55 Insider Trans2.94% Shs Float94.19M Perf Month-18.22%
Enterprise Value1.23B PEG- EPS next Q-0.15 Inst Own41.58% Short Float17.84% Perf Quarter-24.12%
Income-68.43M P/S601.62 EPS this Y25.52% Inst Trans-3.06% Short Ratio14.34 Perf Half Y-63.48%
Sales0.31M P/B- EPS next Y-18.39% ROA-17.24% Short Interest16.80M Perf YTD-62.30%
Book/sh-7.71 P/C0.57 EPS next 5Y-1.29% ROE- 52W High2.59 -75.40% Perf Year-74.51%
Cash/sh1.12 P/FCF- EPS past 3/5Y11.32% - ROIC- 52W Low0.46 38.43% Perf 3Y-93.61%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin-1497.39% Volatility16.75% 16.88% Perf 5Y-
Dividend TTM- EV/Sales3967.43 EPS Y/Y TTM-5.63% Oper. Margin-58713.73% ATR (14)0.12 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.96 Sales Y/Y TTM- Profit Margin-22362.09% RSI (14)43.63 Recom2.40
Dividend Gr. 3/5Y- - Current Ratio10.96 EPS Q/Q16.70% SMA20-17.25% Beta1.37 Target Price3.50
Payout- Debt/Eq- Sales Q/Q- SMA50-19.39% Rel Volume1.32 Prev Close0.58
Employees204 LT Debt/Eq- EarningsMay 12 AMC SMA200-53.32% Avg Volume1.17M Price0.64
IPOJun 30, 2021 Option/ShortYes / Yes EPS/Sales Surpr.16.83% - Trades Volume1,540,594 Change10.11%
Date Action Analyst Rating Change Price Target Change
Jun-30-25Downgrade BofA Securities Neutral → Underperform $1
Sep-30-24Initiated JP Morgan Neutral
Sep-10-24Initiated Guggenheim Buy $6
Mar-07-24Resumed Morgan Stanley Equal-Weight $3
Jan-02-24Downgrade BofA Securities Buy → Neutral
Jul-25-23Initiated BTIG Research Buy $16
Dec-21-22Initiated Jefferies Buy $15
Nov-10-22Initiated Morgan Stanley Equal-Weight $13
Oct-18-22Initiated UBS Buy $18
Oct-14-22Initiated Citigroup Buy $16
Jul-01-25 12:43PM
Jun-30-25 09:36AM
May-12-25 04:15PM
Mar-21-25 09:55AM
Mar-17-25 07:30AM
07:30AM Loading…
Jan-07-25 07:30AM
Nov-26-24 07:30AM
Nov-12-24 07:30AM
Nov-05-24 07:30AM
Oct-22-24 07:02PM
Oct-14-24 07:30AM
Oct-09-24 07:30AM
Sep-04-24 01:33PM
Sep-03-24 07:30AM
Aug-27-24 07:30AM
07:00AM Loading…
Aug-09-24 07:00AM
Jun-27-24 05:52AM
Jun-26-24 02:10PM
Jun-17-24 07:00AM
Jun-11-24 09:35PM
07:40AM
Jun-10-24 04:15PM
07:32AM
06:30AM
May-29-24 07:00AM
May-21-24 07:00AM
May-10-24 03:43PM
01:54PM
07:48AM
07:00AM
06:05AM Loading…
Mar-25-24 06:05AM
Mar-21-24 07:49PM
Feb-29-24 04:05PM
Dec-29-23 08:22AM
Dec-13-23 09:55AM
Nov-30-23 06:05AM
Nov-24-23 06:40AM
Nov-21-23 06:05AM
Nov-17-23 01:38PM
Nov-16-23 09:35AM
Nov-14-23 07:04AM
06:05AM
Nov-13-23 05:02PM
Oct-30-23 04:12PM
Oct-17-23 09:35AM
Oct-16-23 02:50PM
Oct-12-23 03:05PM
Sep-06-23 12:14PM
Sep-05-23 06:05AM
Aug-31-23 10:33AM
Aug-29-23 01:16PM
Aug-11-23 02:21PM
Aug-10-23 04:10PM
Jul-18-23 06:05AM
Jul-17-23 06:05AM
Jun-13-23 12:05PM
Jun-01-23 04:05PM
May-11-23 04:01PM
May-04-23 06:05AM
Apr-25-23 02:00PM
Mar-28-23 04:12PM
Mar-03-23 06:05AM
Jan-11-23 07:48AM
Jan-10-23 04:05PM
Dec-27-22 11:05AM
08:46AM
Dec-22-22 06:05AM
Nov-16-22 11:22AM
Nov-14-22 06:05AM
Nov-11-22 04:05PM
Nov-03-22 06:05AM
Oct-14-22 12:00PM
Sep-23-22 06:15AM
Sep-08-22 06:05AM
Aug-31-22 06:05AM
Aug-11-22 05:30PM
10:01AM
Jul-20-22 08:00AM
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 22 '25Buy0.71387,393276,36673,842,723Apr 24 04:15 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 17 '25Buy0.7525,00018,69073,455,330Apr 21 04:37 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 16 '25Buy0.75100,00074,82073,430,330Apr 18 04:15 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 15 '25Buy0.70468,000326,00973,330,330Apr 16 05:04 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 14 '25Buy0.73268,105194,59172,862,330Apr 16 05:04 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 10 '25Buy0.611,032,218627,69272,592,325Apr 14 04:30 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 11 '25Buy0.611,9001,15572,594,225Apr 14 04:30 PM
Weber Darin J.Chief Regulatory OfficerSep 19 '24Sale2.5016,41241,030103,480Sep 20 04:44 PM
DARIN J WEBEROfficerSep 19 '24Proposed Sale2.3916,41239,225Sep 19 04:27 PM
Weber Darin J.Chief Regulatory OfficerJul 26 '24Sale2.508262,065119,892Jul 29 04:02 PM